Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Reader Login
Indian Journal of Medical and Paediatric Oncology
Search Article 
Advanced search 
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   1995| December  | Volume 16 | Issue 4  
    Online since May 30, 2009

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Intraperitoneal cisplatin in the management of malignant ascites.
A Sharma, DP Punia, RK Chaudhary, MR Bardia, RL Solanki, HS Kumar, S Kumar
December 1995, 16(4):213-218
20 patients with malignant ascites were treated with intraperitoneal(IP) cisplatin which included 16 cases of carcinoma ovary and one case each of cancer breast, colon, stomach and mesothelioma of peritoneum. Out of 20 patients, 16 patients had excellent local control of disease with absence of effusion and improving Karnofsky's scale upto 90 to 100 percent(14 cases of cancer ovary and one case each of carcinoma breast and mesothelioma of peritoneum). Two cases , one ach of carcinoma colon and stomach, and two cases of carcinoma ovary with advanced disease did not respond to intraperitoneal cisplatin. Infusions of cisplatin were generally well tolerated by the patients. No sign of myelosuppression, nephrotoxicity, neuropathy or ototoxicity was observed in the present study. Acute toxicity consisting of mild nausea, vomiting(Grade 1-2 according to WHO scale)and anorexia was observed in most of patients. The results obtained in the current study suggest that intraperitoneal cisplatin is an effective therapy for immediate control of malignant ascites with minimal side effects.
[ABSTRACT]   Full text not available   
  680 0 -
Small cell carcinoma of cervix with bilateral adrenal metastases.
MH Mankad, PS Dave, AS Mehta, AS Kapadia, KS Dave
December 1995, 16(4):239-243
Small Cell Carcinoma of cervix is a rare entity. A 42 year old woman presented with stage Ib cervical cancer, biopsied specimen on light microscopy proved to be of small cell variety. Inspite of radical surgery and post operative adjuvant chemotherapy, she developed bilateral adrenal metastases. The patient was than given aggressive second line chemotherapy but the metastatic lesion was persistent. Excision of persistent adrenal metastases was planned after the metastatic work up. On CT scan, patient had multiple brain metastases. After three months she succumbed to the disease.
[ABSTRACT]   Full text not available   
  660 0 -
Primary ovarian tumor-correlation between ultrasonography, ct scan and surgery.
MS Sandhu, AK Gupta, SM Haq
December 1995, 16(4):225-235
Ovarian tumors are the second most common cause of gynecological malignancies in India. We undertook this study in 21 patients with clinical suspicion of ovarian neoplasm, all of whom were evaluated by Ultrasound(US) and Computed Tomography(CT). Each patient was evaluated for pelvic and extra pelvic disease. Sixteen of these patients underwent surgery while 5 were evaluated by fine needle aspiration biopsy. Nineteen of these finally proved to be primary ovarian tumors while 2 were non ovarian masses. Both these modalities had similar results for pelvic disease evaluation. CT proved to be superior for evaluating extra pelvic disease primarily because of its ability to detect omental/peritoneal deposits, gastrointestinal tract(GIT) involvement and liver deposits better than US. We recommend CT as the investigation of choice between these 2 modalities.
[ABSTRACT]   Full text not available   
  613 0 -
Phase II trial of paclitaxel in cases of advanced ovarian carcinoma and other malignancies.
BS Parikh, R Gopal, JN Kulkarni, SH Advani
December 1995, 16(4):219-224
Paclitaxel is a new anti-tumour agent. The drug hs been found useful in advanced ovarian malignancies and various other malignancies. Phase II trial of this drug was conducted at Tata Memorial Hospital to study efficacy, safety and toxicity profile of this drug. The response rate was 18 percent for advanced ovarian carcinoma and partial response was seen in one case of choriocarcinoma. Acceptable degree of myelosuppression and alopecia were seen as side effect. No hypersensitivity reactions were noticed. We conclude that Paclitaxel is a reasonably safe drug with good efficacy in various malignancies.
[ABSTRACT]   Full text not available   
  546 0 -
Preliminary experience with an implanted catheter system in oncologic patients.
D Radheshyam, R Ramani, RP Deo, A Raghavan
December 1995, 16(4):244-247
Modern day management of cancer patients very often requires administration of intravenous of combination chemotherapeutic agents. Peripheral venous access, may frequently become difficult necessitating reliable Central Venous access. This is a retrospective review of our experience with cancer patients who had completely implanted venous access ports. From 1991 to 1994 there were ten patients. The ports remained in situ for an average of 9 months. Two ports functioned for more than a year. Average of 6 chemotherapies were given through each port. Catheter performance in 50 percent of cases was excellent. The commonest complication was sepsis which required removal of two ports. Totally implantable ports are a relatively safe and reliable method of long term venous access in cancerr patients requiring chemotherapy.
[ABSTRACT]   Full text not available   
  529 0 -
Aspiration cytology of the hydrocoele tamoxifen and endometrial carcinoma-a case report.
A Kapadia, CL Pai
December 1995, 16(4):236-238
A case of 53 year old female patient who developed stage la, well differentiated endometrial carcinoma after taking adjuvant Tamoxifen for breast cancer is reported.
[ABSTRACT]   Full text not available   
  488 0 -
Endometrial cancer.
AS Kapadia, AD Desai
December 1995, 16(4):203-212
Full text not available   
  367 0 -
Developments in the chemotherapy of advanced epithelial ovarian cancer.
L Kumar
December 1995, 16(4):199-202
Full text not available   
  319 0 -
KC Muralidharan
December 1995, 16(4):248-249
Full text not available   
  246 0 -